Joaquin Duato does not mince words. The chairman and chief executive of Johnson & Johnson believes a cure for certain cancers sits within reach over the next decade. Others may shift from deadly threats to conditions patients manage for years. The comments, delivered at the WSJ Leadership Institute CEO Summit in London, signal how far the company’s oncology bet has come. And how high Duato has set the bar.
Duato told the gathering that finding a cure for certain cancers and turning others into chronic diseases stands as a realistic goal for the coming decade, the Wall Street Journal reported. He added that eradicating cancer entirely while helping people live longer, healthier lives represents the company’s ultimate goal. The statement aligns with J&J’s public aim to become the No. 1 oncology company by 2030, with oncology sales potentially hitting $50 billion by decade’s end.
Success won’t arrive through hope alone. J&J has poured resources into multiple myeloma treatments that now deliver impressive results. Darzalex generated nearly $14.4 billion in sales during 2025, a 23% jump from the prior year. Carvykti, the BCMA CAR-T therapy, saw its quarterly sales climb 66% to $555 million in the fourth quarter even as it missed some Wall Street forecasts. Tecvayli added another $176 million that period, up 21%. These figures come from BioPharma Dive.
But the real action lies ahead. Recent data on Tecvayli combined with Darzalex showed a 54% reduction in the risk of death versus Darzalex plus dexamethasone in a late-stage study. Monotherapy Tecvayli cut the risk of disease progression or death by 71% and death by 40% in patients largely refractory to prior therapies. Such outcomes fuel Duato’s confidence. “Our aim as Johnson and Johnson is not only to extend lives but to cure multiple myeloma,” he said in a CNBC interview discussing the company’s five-year study. “We are presenting data here… to get the patients in multiple myeloma to a cure.”
Ambitious. Concrete. Backed by numbers.
The company isn’t stopping at blood cancers. Its pipeline spans lung, bladder, prostate and more. Rybrevant plus Lazcluze delivered overall survival benefits in EGFR-mutated non-small cell lung cancer, the first chemotherapy-free combination to do so versus osimertinib in certain Asian patients. Inlexzo, approved last year for non-muscle invasive bladder cancer, produced complete responses in 82% of patients without reinduction therapy. These advances appear in J&J’s own pipeline updates and press materials.
Acquisitions supply fresh platforms. J&J agreed this month to buy Firefly Bio for $1 billion to gain the Firelink degrader antibody conjugate technology. The approach targets KRAS-driven tumors, long considered nearly undruggable. Patients with such mutations often face survival measured in months. John Reed, J&J’s executive vice president of innovative medicine research and development, stated that “KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years. We believe the proprietary Firelink platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumors.” The deal, reported by Yahoo Finance, is expected to close before the end of 2026.
Earlier moves brought Halda Therapeutics and its RIPTAC platform for regulated induced proximity targeting chimeras. The company also invested more than $1 billion in a new cell therapy manufacturing site in Pennsylvania. These steps address both innovation and capacity. They reflect a deliberate effort to broaden modalities beyond traditional small molecules and antibodies.
Duato’s optimism extends to artificial intelligence. He noted AI already speeds medicine development at J&J. Exactly how much that acceleration will lift the bottom line remains an open question. Still, the technology joins a broader toolkit that includes prevention, early detection, bispecific antibodies, CAR-T therapies and now degraders.
The vision sounds sweeping. J&J’s corporate oncology page declares a “bold vision to eliminate cancer.” Employees work “tirelessly to get in front of cancer and create a future where cures are a reality and cancer is eradicated.” The language matches the CEO’s tone. Yet progress must overcome stubborn realities. Not every tumor yields to current approaches. Resistance emerges. Access barriers persist across regions. Competition from other large pharmaceutical players keeps intensifying.
Financially the picture looks solid. J&J posted first-quarter 2026 revenue of $24.1 billion, up roughly 10% from a year earlier. Full-year 2026 sales guidance now sits between $100.3 billion and $101.3 billion. Oncology stands as a primary growth engine amid patent pressures on older drugs such as Stelara. The company aims to triple its oncology sales by the end of the decade. That requires flawless execution across clinical, regulatory and commercial fronts.
Multiple myeloma offers the clearest proof point so far. Five-year data presented at medical meetings show deep responses and potential for treatment-free intervals in some patients. Combinations of bispecifics and cell therapies push complete response rates higher than many once thought possible. Doctors increasingly talk of functional cures in subsets of patients. Duato wants to turn those pockets of success into standard outcomes.
So the strategy mixes near-term revenue drivers with longer-term platform bets. Darzalex and Carvykti generate cash today. Firefly and similar acquisitions seed tomorrow’s breakthroughs. Pipeline assets target lymphoma, prostate cancer and solid tumors with novel mechanisms. The holistic approach spans interception before tumors fully develop all the way through advanced disease management.
Critics might call the cure rhetoric aspirational marketing. Duato frames it as measurable ambition. “The goal for us is try to eliminate cancer,” he said in a recent WSJ Leaders podcast. “That’s a high goal and we are already making significant progress in certain areas.” Results from ongoing trials will test the claim. Positive overall survival data in lung cancer and deeper responses in myeloma already move the needle.
Investors appear to buy the story. J&J shares have held steady as oncology momentum builds. The company’s market position in multiple myeloma looks particularly strong with multiple approved agents and more combinations advancing. Yet success in solid tumors, where most cancer deaths occur, will determine whether the No. 1 ranking by 2030 becomes fact or footnote.
One thing seems clear. J&J has committed capital, talent and executive attention to oncology in ways few predicted a decade ago. The acquisition spree, manufacturing buildout and pipeline breadth reveal a seriousness of purpose. Duato, who became CEO in 2022, has sharpened the company’s focus on six priority areas with oncology near the top.
Patients wait for outcomes, not projections. A mother diagnosed with lung cancer wants more than extended survival. She wants her children to grow up without fear of recurrence. A man with multiple myeloma hopes to reach retirement disease-free. Those human stakes drive the research. They also explain why Duato speaks so directly about cures.
The coming years will reveal how much of that vision translates into approved therapies. Data readouts expected in 2026 and 2027 across lung, bladder and blood cancers will offer early clues. Regulatory filings for new combinations and expanded labels already sit in the queue. Manufacturing scale-up must match demand without quality lapses.
J&J enters this period with advantages. Decades of experience in antibodies and now cell therapies. A sales infrastructure that reaches global markets. Financial strength to absorb the occasional clinical setback. The Firefly deal adds a platform that could unlock targets once dismissed. Similar bets on other novel modalities may follow.
But oncology rarely offers straight lines. Biology fights back. Trial failures happen even to the best programs. Competitors race forward with their own bispecifics, antibody-drug conjugates and gene therapies. Pricing pressure from payers and governments adds another layer of complexity.
Duato acknowledges the challenges without losing the thread. His message at the London summit mixed realism with determination. Cures for some. Chronic management for others. Steady progress against a disease that has defined medicine for generations. The industry watches closely. So do patients.
Whether J&J hits the top oncology spot by 2030 or delivers on the cure timeline matters less than the direction of travel. Each positive dataset, each new platform, each manufacturing dollar invested narrows the gap between ambition and reality. The CEO has drawn the map. Now the organization must follow it.
WebProNews is an iEntry Publication